Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 17 Apr 2016 Results assessing pharmacokinetics of Abt-493 and Abt-530 combination therapy presented at The International Liver Congress 2016.
- 20 Oct 2015 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 16 Oct 2015 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.